Voceryq offers adults with recurrent respiratory papillomatosis a new treatment approach that targets the underlying viral infection and may reduce the need for repeated surgeries.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the United States, for adults with recurrent respiratory papillomatosis (RRP).
Announced October 30, 2026, the approval represents an important advancement in treating a rare, chronic respiratory disease caused by human papillomavirus (HPV). Unlike conventional treatments that primarily remove growths from the airway, Voceryq is designed to stimulate the body’s immune system to recognize and attack cells infected with the HPV types responsible for the disease.
Understanding recurrent respiratory papillomatosis
RRP is caused primarily by HPV types 6 and 11 and results in wart-like growths, called papillomas, in the respiratory tract. These growths most commonly develop around the larynx (voice box) and vocal cords.
Patients may experience persistent hoarseness, voice changes, coughing, and, in severe cases, breathing difficulties. Surgery can remove the growths, but it does not eliminate the underlying viral infection. Consequently, some patients require repeated surgical procedures over many years to maintain their airways and manage symptoms.
Voceryq introduces a different treatment strategy by targeting the cells infected with the virus rather than simply removing the resulting growths.
How the new immunotherapy works
Developed by Inovio Pharmaceuticals, Voceryq uses two plasmids, which are small circular DNA molecules, to deliver genetic instructions into the body’s cells.
One plasmid contains instructions for producing specific HPV proteins, while the second promotes an immune response through a molecule called interleukin-12 (IL-12). Together, these components are intended to stimulate the immune system to recognize and attack cells infected with HPV types 6 and 11.
The treatment is administered by intramuscular injection using the CELLECTRA 5PSP device, which applies brief electrical pulses through a process called electroporation. These pulses temporarily increase the permeability of cell membranes, helping the plasmid DNA enter cells.
This combination of DNA-based immunotherapy and device-assisted delivery illustrates an emerging approach to treating diseases associated with persistent viral infections.
Clinical results and accelerated approval
FDA based its decision on clinical data from an open-label, multicenter study involving 32 adults with RRP. Patients entering the study had undergone repeated surgical procedures to remove respiratory papillomas. Among 26 patients who had been through at least three surgeries before treatment, seven patients (27%) required no surgical intervention during the first year following Voceryq treatment.
The FDA granted accelerated approval based on a reduction in surgical frequency, an intermediate clinical endpoint considered reasonably likely to predict clinical benefit.
However, accelerated approval does not eliminate the requirement to demonstrate clinical benefit. Inovio must conduct post-approval clinical trials to verify and further characterize the treatment’s benefits.
Safety and regulatory considerations
The most commonly reported adverse reactions included injection-site reactions, headache, fatigue, hypertension, nausea, and dizziness. The electroporation delivery procedure may also cause temporary muscle contractions, pain, bleeding, lightheadedness, and other administration-related effects.
Voceryq previously received FDA Breakthrough Therapy and Orphan Drug designations, reflecting its potential importance for patients with a serious condition and limited treatment options.
MDP regulatory intelligence perspective
Voceryq’s approval is significant for several reasons. First, it introduces a new FDA-approved therapeutic approach based on plasmid DNA immunotherapy, expanding the range of technologies available for treating diseases associated with persistent viral infections.
Second, the approval highlights the role of device-assisted delivery in advanced biologic therapies. The CELLECTRA electroporation system is an integral part of administering Voceryq, demonstrating how drug and device technologies can work together to deliver innovative treatments.
Finally, the decision illustrates the FDA’s accelerated approval pathway in practice. The agency has authorized access based on encouraging clinical evidence while requiring additional studies to verify the anticipated benefit.
For patients with RRP, the most meaningful outcome may be a reduction in the repeated surgical procedures that have historically defined management of the disease. For the biotechnology and regulatory communities, Voceryq represents another important development in the application of genetic technologies to therapeutic immunology.
Editorial comment: one distinction worth observing is that Voceryq is designed to target HPV-infected cells, but the approval does not establish that it eliminates the underlying infection or cures RRP. The demonstrated reduction in surgical burden is encouraging, while confirmatory studies remain necessary.
FDA Warning Letter for Stem Cell and Placenta Products
FDA challenges claims that biological products can treat serious diseases without demonstrating their safety and effectiveness through the agency's approval processStem cell therapies and products derived from human placental tissue have attracted considerable...
FDA Challenges Tides Medical’s Class I Device Classification
FDA's warning letter to Tides Medical illustrates how a device's intended use, not its manufacturer's chosen product code, determines its regulatory requirementsCan a medical device manufacturer classify an innovative wound-treatment technology as a Class I device...
First T-Cell Therapy to Reduce Disease after Cell Transplant
FDA Approves First Regulatory T-Cell Therapy to Reduce Chronic Graft-versus-Host Disease After Stem Cell TransplantThe First Regulatory T (Treg) Cell-Based Immunotherapy The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T (Treg)...
Casgevy Gene Therapy Expanded to 2-Year-Old Children
FDA Expands Casgevy Gene Therapy Approval to Children as Young as 2 with Sickle Cell DiseaseFirst CRISPR-based gene therapy approved for young children with sickle cell disease The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Casgevy...
FDA Approves First Gene Therapy for Genetic Hearing Loss
FDA Approves First Gene Therapy for Genetic Hearing LossRapid Review and Breakthrough Science Converge in Landmark OTOF Therapy The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first gene therapy for a form of inherited hearing loss caused by mutations in...
FDA Streamlines Biosimilar Development to Reduce Drug Costs
FDA Moves to Streamline Biosimilar Development and Reduce Drug Costs The U.S. Food and Drug Administration (FDA) has announced new steps to simplify the development pathway for biosimilar medicines, a move intended to reduce development costs and improve patient...
FDA’s Orphan Drug Program
Expedite Development of New Orphan Drugs The FDA's Orphan Drug Program is designed to encourage the development of drugs and biologics for the treatment, diagnosis, or prevention of rare diseases or conditions, often referred to as orphan diseases. Here are the key...
